{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-23-000026","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.012398+00:00","generated_at":"2026-06-12T21:40:30.578694+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q2 revenues $595M (+12% YoY), raises FY VOXZOGO guidance to $400-440M","bullets":["Q2 total revenues $595.3M (+12% YoY); GAAP net income $56.0M ($0.29 diluted EPS); Non-GAAP income $105.2M ($0.54 diluted EPS).","Record H1 2023 revenues of $1.19B (+13% YoY); VOXZOGO Q2 sales surged 229% to $113.3M.","Full-year VOXZOGO revenue guidance raised to $400-440M (was $380-430M); GAAP net income guidance raised to $165-215M.","US approved ROCTAVIAN on June 29; commercial launch started; European reimbursement negotiations continue.","Pivotal program for VOXZOGO in hypochondroplasia to begin in Q4 2023; ongoing studies for age expansion and pipeline updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-23-000026","json":"https://secwatch.observer/filing/0001048477-23-000026.json","markdown":"https://secwatch.observer/filing/0001048477-23-000026.md","text":"https://secwatch.observer/filing/0001048477-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/0001048477-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/bmrn-20230731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:40:30.578694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc60824d1fb9a4a0e8b104e6b5a6f95ba1f95022","claim":"BIOMARIN PHARMACEUTICAL INC updated its the six months and second quarter ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On July 31, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/0001048477-23-000026-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months and second quarter ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}